Maze Therapeutics (MAZE) Interest Coverage Ratio (2024 - 2026)

Maze Therapeutics (MAZE) reported Interest Coverage Ratio of 7.09 for Q1 2026, up 2185.96% sequentially from 0.34 in Q4 2025.

Maze Therapeutics (MAZE) Interest Coverage Ratio (2024 - 2026) Analysis & Trends

Maze Therapeutics (MAZE) has 3 years of Interest Coverage Ratio data on file, last reported at 7.09 in Q1 2026.

  • For the quarter ending Q1 2026, Interest Coverage Ratio changed N/A year-over-year to 7.09; the trailing twelve-month figure through Mar 2026 stood at 35.78 (changed N/A YoY), and the FY2025 full-year result was 0.87, down 233.77% from the prior year.
  • Interest Coverage Ratio advanced to 7.09 in Q1 2026, from 0.34 in the prior quarter.
  • In the past five years, Interest Coverage Ratio ranged from a high of 7.09 in Q1 2026 to a low of 0.34 in Q4 2025.
  • A 3-year average of 2.14 and a median of 0.34 in 2024 frame the typical range for Interest Coverage Ratio.
  • Peak annual rise in Interest Coverage Ratio reached 0.73% in 2025, while the deepest fall reached 0.73% in 2025.
  • Tracing MAZE's Interest Coverage Ratio over 3 years: stood at 0.34 in 2024, then decreased by 0.73% to 0.34 in 2025, then soared by 2185.96% to 7.09 in 2026.
  • Business Quant data shows MAZE's Interest Coverage Ratio at 7.09 in Q1 2026, 0.34 in Q4 2025, and 0.34 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 658.42
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 7.60
4 NuCana 279.75 Bn 279.75 Bn - -0.22
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.71
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 22.72
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -0.38
10 Maze Therapeutics 1.49 Bn 1.49 Bn 18.21 Mn 7.09

Historic Data

Download Data
DateValue
Mar 31, 2026 7.09
Dec 31, 2025 -0.34
Dec 31, 2024 -0.34